江苏新治疗肺结节去哪最好上海乳腺结节术后可以吃无花果吗,上海肺肿瘤是怎么引起的,上海桦树汁能消除肺结节,上海肾瘤吃什么中药治疗,上海支气管炎的症状有哪些,上海肺上有结节是怎么回事好不好治,江苏治疗乳腺结节的医院哪个好点

LOS ANGELES, March 27 (Xinhua) -- Walnuts have a combination of more healthful antioxidants and higher quality antioxidants than any other nut, U.S. researchers have found.Study findings were presented on Sunday at the 241st National Meeting & Exposition of the American Chemical Society (ACS) in Anaheim, Southern California.Nuts contain plenty of high-quality protein that can substitute for meat, vitamins and minerals, dietary fiber, and are dairy- and gluten-free, ACS researchers said in the study.Moreover, nuts contain healthful polyunsaturated and monosaturated fats rather than artery-clogging saturated fat, according to the study.The researchers based their conclusion on analysis of antioxidants in nine different types of nuts: walnuts, almonds, peanuts, pistachios, hazelnuts, Brazil nuts, cashews, macadamias and pecans.They found that walnuts have the highest levels of antioxidants, with plenty of high-quality protein that can substitute for meat, vitamins and minerals, dietary fiber, and are dairy- and gluten-free.The latest study adds more evidence that walnuts are top nuts for heart-healthy antioxidants, the researchers said.Previous studies showed that regular consumption of small amounts of nuts or peanut butter can decrease the risk of heart disease, certain kinds of cancer, gallstones, Type 2 diabetes, and other health problems.But the latest study is the first to compare both the amount and quality of antioxidants found in different nuts."Walnuts rank above peanuts, almonds, pecans, pistachios and other nuts," said Joe Vinson, Ph.D., who led the latest study."A handful of walnuts contains almost twice as much antioxidants as an equivalent amount of any other commonly consumed nut. But unfortunately, people don't eat a lot of them. This study suggests that consumers should eat more walnuts as part of a healthy diet."

NAIROBI, Jan. 28 (Xinhua) -- Although exact details surrounding the situation are not known at this time, there are indications that the fishing vessel TAI JUAN 227 from China's Taiwan has been released from pirate control, the EU anti piracy mission said on Friday.The vessel, which had a crew of 28 at the time of the attack, was pirated on May 6, 2010 while operating 700 Nm North East of Seychelles.EU Naval Force spokesman Paddy O'Kennedy said in a statement that although direct contact with the crew has not been possible, the vessel's owners apparently received a call from the master stating that they had been released but that they did not know why.According to the EU naval force, the crew were provided with fresh food and water by a U.S. warship after the release. The vessel is currently heading away from Somalia.The naval spokesman also said that there is confusion surrounding the details of the release as, until three days ago, the FV TAI YUAN 227 was suspected as being used as a pirate mothership.The Gulf of Aden, a body of water between Somalia and Yemen, is the main sea route between Europe and Asia.Tankers carrying Middle East oil through the Suez Canal must pass first through the Gulf of Aden. Pirate gangs operating along Somalia's coastline have become increasingly audacious over the past two years, hijacking dozens of merchant ships and their crews to earn ransoms that can top 1 million U.S. dollars per ship.So far the fledgling Somali government has not dared go after the pirate strongholds, since pirate leaders have more power than the beleaguered government.

WASHINGTON, March 25 (Xinhua) -- NASA's Stardust spacecraft depleted fuel and ceased operation on Thursday after a 12-year run, the U.S. space agency said Friday."This is the end of the spacecraft's operations, but really just the beginnings of what this spacecraft's accomplishments will give to planetary science," said Lindley Johnson, Stardust-NExT and Discovery program executive at NASA headquarters in Washington."The treasure-trove of science data and engineering information collected and returned by Stardust is invaluable for planning future deep space planetary missions."Artist's concept of Stardust spacecraft nearing EarthLaunched on Feb. 7, 1999, Stardust flew past the asteroid named Annefrank and traveled halfway to Jupiter to collect the particle samples from the comet Wild 2. The spacecraft returned to Earth's vicinity to drop off a sample return capsule eagerly awaited by comet scientists.NASA re-tasked the spacecraft as Stardust-NExT to perform a bonus mission and fly past comet Tempel 1, which was struck by the Deep Impact mission in 2005. The mission collected images and other scientific data to compare with images of that comet collected by the Deep Impact.The Stardust-NExT met all mission goals, and the spacecraft was extremely successful during both missions. From launch until final rocket engine burn, it travelled approximately 3.54 billion miles.After the mileage logged in space, the Stardust team knew the end was near for the spacecraft. With its fuel tank empty and final radio transmission concluded, the most traveled comet hunter will move from NASA's active mission roster to retired."This kind of feels like the end of one of those old western movies where you watch the hero ride his horse toward the distant setting sun -- and then the credits begin to roll," said Stardust-NExT project manager Tim Larson from NASA's Jet Propulsion Laboratory in Pasadena, California. "Only there's no setting sun in space."

WASHINGTON, March 4 (Xinhua) -- New data suggest that the epilepsy drug Topamax (topiramate) and its generic versions increase the risk for the birth defects cleft lip and cleft palate in babies born to women who use the medication during pregnancy, the U.S. Food and Drug Administration (FDA) said Friday in a statement.Before prescribing topiramate, approved to treat certain types of seizures in people who have epilepsy, health care professionals should warn patients of childbearing age about the potential hazard to the fetus if a woman becomes pregnant while using the drug, the FDA said.Topiramate also is approved to prevent migraine headaches, but not to relieve the pain of migraines."Health care professionals should carefully consider the benefits and risks of topiramate when prescribing it to women of childbearing age," said Russell Katz, director of the Division of Neurology Products in the FDA's Center for Drug Evaluation and Research. "Alternative medications that have a lower risk of birth defects should be considered."Cleft lip and cleft palate, collectively called oral clefts, are birth defects that occur when parts of the lip or palate do not completely fuse together early in the first trimester of pregnancy, a time when many women do not know they are pregnant.The defects range from a small notch in the lip to a groove that runs into the roof of the mouth and nose, possibly leading to problems with eating, talking, and to ear infections. Surgery often is performed to close the lip and palate and most children do well after treatment.Data from the North American Antiepileptic Drug (AED) Pregnancy Registry indicate an increased risk of oral clefts in infants exposed to topiramate during the first trimester of pregnancy. Infants exposed to topiramate as a single therapy experienced a 1.4 percent prevalence of oral clefts, compared with a prevalence of 0.38 percent - 0.55 percent in infants exposed to other antiepileptic drugs.Infants of mothers who did not have epilepsy and were not being treated with other antiepileptic drugs had a prevalence of 0.07 percent. Similar data from the United Kingdom Epilepsy and Pregnancy Register supported the North American AED Pregnancy Registry data.According to the FDA, before starting topiramate, pregnant women and women of childbearing potential should discuss other treatment options with their health care professional.